Movement Disorders (revue) - Exploration (Accueil)

Index « PascalFr.i » - entrée « Primates »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Primaire < Primates < Primidone  Facettes :

List of bibliographic references indexed by Primates

Number of relevant bibliographic references: 22.
[0-20] [0 - 20][0 - 22][20-21][20-40]
Ident.Authors (with country if any)Title
001237 (2012) Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; QIN LI [République populaire de Chine] ; Jonathan Brotchie [Canada] ; Erwan Bezard [République populaire de Chine, France]A Critique of Available Scales and Presentation of the Non-Human Primate Dyskinesia Rating Scale
001363 (2011) Christopher Kobylecki [Royaume-Uni] ; Michael P. Hill [Canada] ; Alan R. Crossman [Royaume-Uni] ; Paula Ravenscroft [Royaume-Uni, Canada]Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease
001612 (2011) Anne-Sophie Rolland [France] ; Carine Karachi [France] ; Marie-Paule Muriel [France] ; Etienne C. Hirsch [France] ; Chantal François [France]Internal pallidum and substantia nigra control different parts of the mesopontine reticular formation in primate
001786 (2011) Raymond T. Bartus [États-Unis] ; Christopher D. Herzog [États-Unis] ; Yaping Chu [États-Unis] ; Alistair Wilson [États-Unis] ; Lamar Brown [États-Unis] ; Joao Siffert [États-Unis] ; Eugene M. Johnson Jr. [États-Unis] ; C. Warren Olanow [États-Unis] ; Elliott J. Mufson [États-Unis] ; Jeffrey H. Kordower [États-Unis]Bioactivity of AAV2‐neurturin gene therapy (CERE‐120): Differences between Parkinson's disease and nonhuman primate brains
001830 (2011) Erwan Bezard [France] ; Serge Przedborski [États-Unis]A tale on animal models of Parkinson's disease
001C68 (2010) Tomas Bjorklund [Suède] ; Jeffrey H. Kordower [États-Unis]Gene therapy for Parkinson's disease
001F06 (2010) Tom H. Johnston [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Juha-Matti Savola [Suisse] ; Jonathan M. Brotchie [Canada]The α2 Adrenergic Antagonist Fipamezole Improves Quality of Levodopa Action in Parkinsonian Primates
001F23 (2010) Kayhan A. Tayarani-Binazir [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; C. Warren Olanow [États-Unis] ; Peter Jenner [Royaume-Uni]Pramipexole Combined with Levodopa Improves Motor Function but Reduces Dyskinesia in MPTP-Treated Common Marmosets
002578 (2008) Naomi P. Visanji [Canada] ; Rob M. A. De Bie [Canada, Pays-Bas] ; Tom H. Johnston [Canada] ; Andrew C. Mccreary [Pays-Bas] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada]The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson's disease
002675 (2008) Peter Jenner [Royaume-Uni]Preventing and controlling dyskinesia in Parkinson's disease—A view of current knowledge and future opportunities
003143 (2006) Susan H. Fox [Canada] ; Anthony E. Lang [Canada] ; Jonathan M. Brotchie [Canada]Translation of nondopaminergic treatments for levodopa‐induced dyskinesia from MPTP‐lesioned nonhuman primates to phase IIa clinical studies: Keys to success and roads to failure
003277 (2006) Naomi P. Visanji [Canada] ; Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Donna Pires [Canada] ; Valerie Voon [Canada, États-Unis] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada]Pharmacological characterization of psychosis‐like behavior in the MPTP‐lesioned nonhuman primate model of Parkinson's disease
003652 (2006) Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Naomi P. Visanji [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada]Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of parkinson's disease
003707 (2005) Carine Karachi [France] ; Jérôme Yelnik [France] ; Dominique Tandé [France] ; Léon Tremblay [France] ; Etienne C. Hirsch [France] ; Chantal François [France]The pallidosubthalamic projection: An anatomical substrate for nonmotor functions of the subthalamic nucleus in primates
003B08 (2004) Matthew J. Hansard [Royaume-Uni] ; Lance A. Smith [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Sharon C. Cheetham [Royaume-Uni] ; Peter Jenner [Royaume-Uni]The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP‐treated primates
003E57 (2004) Lance A. Smith [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Ghassan Al-Barghouthy [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; Mikko Kuoppamaki [Royaume-Uni, États-Unis] ; Warren Olanow [Finlande] ; Peter Jenner [Royaume-Uni]Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naïve primates
004108 (2003) Lance A. Smith [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Matthew J. Hansard [Royaume-Uni] ; Eleni Maratos [Royaume-Uni] ; Peter Jenner [Royaume-Uni]Effect of pulsatile administration of levodopa on dyskinesia induction in drug‐naïve MPTP‐treated common marmosets: Effect of dose, frequency of administration, and brain exposure
004379 (2002) Igor A. Ilinsky [États-Unis] ; Kristy Kultas-Ilinsky [États-Unis]Motor thalamic circuits in primates with emphasis on the area targeted in treatment of movement disorders
004705 (2001) G. M. Petzinger [États-Unis] ; M. Quik [États-Unis] ; E. Ivashina [États-Unis] ; M. W. Jakowec [États-Unis] ; M. Jakubiak [États-Unis] ; D. Di Monte [États-Unis] ; J. W. Langston [États-Unis]Reliability and validity of a new global dyskinesia rating scale in the MPTP‐lesioned non‐human primate
004872 (2001) Eleni C. Maratos [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Ronald K. B. Pearce [Royaume-Uni] ; Peter Jenner [Royaume-Uni]Antiparkinsonian activity and dyskinesia risk of ropinirole and L‐DOPA combination therapy in drug naive MPTP‐lesioned common marmosets (Callithrix jacchus)
005194 (1998) P. A. Lapchak [États-Unis]A preclinical development strategy designed to optimize the use of glial cell line-derived neurotrophic factor in the treatment of Parkinson's disease

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/PascalFr.i -k "Primates" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/PascalFr.i  \
                -Sk "Primates" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    PascalFr.i
   |clé=    Primates
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024